Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1F | P30939 | 14/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.41 |
| ▸ | CDK2 | P24941 | 2/20 | 0.41 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.41 |
| ▸ | HTR1A | P08908 | 7/20 | 0.40 |
| ▸ | HTR1D | P28221 | 6/20 | 0.40 |
| ▸ | HTR1B | P28222 | 6/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | HTR1E | P28566 | 1/20 | 0.40 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5457234 | 0.91 | MAPK14 (0.39) | HTR1FCCNA2CDK2CCNA1MAPK14 | |
| SCHEMBL5452858 | 0.86 | CDK2 (0.50) | HTR1FCCNA2CDK2CCNA1MAPK7 | |
| SCHEMBL5454768 | 0.84 | FLT3 (0.41) | HTR1FHTR1AMAPK14ACACBFLT3 | |
| SCHEMBL5447010 | 0.84 | KMT2A (0.39) | CCNA2CDK2CCNA1 | |
| SCHEMBL5453832 | 0.80 | ALDH1A1 (0.43) | HTR1FCCNA2CDK2CCNA1HTR2A | |
| SCHEMBL5454692 | 0.79 | HRH4 (0.39) | CCNA2CDK2CCNA1 | |
| SCHEMBL5456520 | 0.77 | HRH4 (0.41) | CCNA2CDK2CCNA1 | |
| SCHEMBL5451831 | 0.77 | CDK2 (0.42) | HTR1FCCNA2CDK2CCNA1 | |
| SCHEMBL5457243 | 0.77 | AURKA (0.47) | CCNA2CDK2CCNA1MAPK7FLT3 | |
| SCHEMBL5453843 | 0.77 | RAB9A (0.46) | CDK2ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070037790-A1 | Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2007-02-15 | — | — | US | claimed |
| US-20070037790-A1 | Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2007-02-15 | — | — | US | disclosed |
| EP-1608364-A1 | BICYCLO-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | Pharmacia Italia S.p.A. (IT) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004080457-A1 | BICYCLO-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PHARMACIA ITALIA S.P.A. (IT) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037790-A1 | Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K15, MAP3K7, MAP3K19 | HTR1F 4498/4885CCNA2 1123/4885CDK2 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.